Recent years have witnessed an upsurge of interest in pharmaceuticals and society, a trend which in part reflects the growing power and influence of the pharmaceutical industry over all our lives, qua patients, consumers and citizens. Medicine costs the National Health Service
This monograph is both a reflection of and response to this upsurge of interest in pharmaceuticals and society, casting further critical sociological light on these developments, discourses and debates. It is possible, in this respect, to point to a variety of themes and issues which taken together demonstrate both progress in sociological research on pharmaceuticals over the years and future prospects.
(i) Medicalisation and Pharmaceuticalisation; doctors, disorders and drugs
The first and perhaps most long-standing sociological theme, has centred on the role of pharmaceuticals in the medicalisation of society. When Illich (1975) , way back in the 1970s, talked of the iatrogenic effects of modern medicine and how the consumption of medical products helped sponsor a 'morbid society', a key target of his critique was our 'overreliance' or 'dependence' on drugs as well as doctors. Others more fully or squarely located within medical sociology, particularly North American medical sociology, have also taken up these themes, albeit in a less radical or libertarian way than Illich. Specific emphasis has been placed by these authors on the expansion of medical jurisdiction and control over more and more areas of our lives, in the name of health and illness (Zola 1970 , Freidson 1970 , Conrad and Schneider 1980a . The role of the pharmaceutical industry within these processes, nonetheless, remained a somewhat muted or neglected theme in the medicalisation literature of the 1970s through to the 1990s, with sociological attention focusing on the power and influence of medicine in the social construction of disease and decisions about its treatment. More recent work, however, has begun to reappraise these processes in the light of current trends and developments regarding the medicalisation of society. Conrad (2007 , Conrad and Leiter 2004 , for example, in updating his previous work in this area (Conrad 1992, Conrad and Schneider 1980a,b) , has pointed to what he terms the 'shifting engines' or 'drivers' of medicalisation over time --see also Clarke et al (2003) for a somewhat different line or emphasis on transitions from medicalisation to so-called 'biomedicalisation'. Whilst the definitional centre of medicalisation remains with doctors, Conrad argues, the primary drivers of medicalisation now pertain to consumerism, managed care markets and developments in biotechnology, including the pharmaceutical industry.
Other more critical commentators (many of whom, significantly, are not sociologists), have taken these arguments one or more steps further, claiming that what may once have been regarded as medicalisation is now best seen as outright 'disease-mongering' in which the helping hand of the pharmaceutical industry looms large. Critics such as Moynihan (Moynihan 2002 , Moynhan and Henry 2006 and Blech (2006) , for example, through a series of case studies, have shown how pharmaceutical companies in collaboration or conjunction with doctors, pressure groups and the media, are no longer simply manufacturers of drugs but of diseases for these drugs to treat! -see also Law (2006) on 'Big Pharma'. A recent issue of the Public Library of Science -Medicine, for instance, devoted a whole section to essays on this very issue, including case studies of a range of diseases or disorders from ADHD (Phillips 2006 ) through erectile dysfunction (Lexchin 2006) and female sexual dysfunction (Tiefer 2006) to biopolar disorder (Healy 2006 (Conrad 2007 (Conrad , 1992 Another key factor or player in these medicalising processes, of course, as Conrad and Leiter's paper on DTCA clearly attests, are the media.
Previous sociological studies, for example, have demonstrated both celebratory and critical media discourses on drugs, depending on the media, format and drug in question, the relative 'newness' of the drug to the market, and its 'newsworthiness' For example, when benzodiazepine tranquillisers were first prescribed in the 1960s they generally received an enthusiastic welcome in the UK and US media and were proclaimed as heralding a new therapeutic era. As their popularity grew, however, their therapeutic value ceased to be newsworthy and a more critical coverage developed, drawing on the comments of a small but growing band of professional and lay critics. Initially, in the 1970s, this concern focused on claims about their overuse as a `chemical crutch' for personal problems, before shifting in the 1980s and 1990s to claims about these drugs' `addictive' potential, Bury 1996a, 1996b) , with users portrayed in the local and national UK press as innocent victims, through no fault of their own, who then tried to withdraw and embark on a `return journey' to normality (Gabe et al 1991) . Moreover, through these forms of mediation and marketing, drugs may come to take on personalities of their own, achieving some sort of quasi-mythic or celebrity status in the popular imagination, construed or constructed as the archetypal hero or villain (see for example Martin 2007 , Nelkin 1995 .
Some of these issues, for instance, are addressed in Williams and colleagues paper on newspaper coverage of the wakefulness-promoting drug Modafinil (brand name Provigil). Constructions of this drug in the print news media, these authors show, range from largely uncritical endorsement of its clinical applications as a 'break through' or 'wonder drug' for a growing list of sleepiness related conditions, to somewhat more cautious or critical coverage of its wider (potential) uptake as a lifestyle drug of choice, or in sport or military contexts. Again we see here, in the guise of this wakefulness-promoting drug, the now familiar if not commonplace rehearsal of concern over the blurring or shifting boundaries between 'treatment' and 'enhancement', and the broader articulation of cultural anxieties about a move to a 24/7 society in which sleep becomes increasingly optional if not obsolete. A notable feature of the paper, in this respect, is the authors preference for the term 'pharmacueticalisation' rather than medicalisation in order to capture these concerns in the press: concerns, that is to say, to do with the potentially widespread use and uptake of pharmaceuticals for diverse purposes which extend far beyond the realms of medicine or the strictly medical.
Another prime expression of the mediation of pharmaceuticals, of course, concerns the Internet or cyber-space/culture --see, for example, Miah and Rich (2008) . This includes not simply access to information on pharmaceuticals via Internet searches, but the purchase of pharmaceuticals through online or e-pharmacies and the sharing of information and support through Internet chat rooms and online forums of various sorts (Fox et al. 2005a,b) . In these and other ways, new opportunities for the mediation of pharmaceuticals are opening up in all our lives, for better or worse, routes that may very well bypass the traditional doctor-patient relationship altogether. Some of these issues Abraham (2007 Abraham ( , 1997 Abraham ( , 1995 Abraham ( , 1994 Abraham ( , 1993 Abraham ( , 2002 
(iii) Consumption and consumerism; Medicines in the marketplace
A third long-standing strand of sociological research on pharmaceuticals concerns what may loosely be termed consumption and consumerism.
Initial work in this area focused on providing a `social audit' of the use of prescribed medicines in the community (e.g. Dunnell and Cartwright 1972) . In the 1980s and 1990s the focus shifted to exploring the social meaning of medications ranging from anti-hypertensives (Morgan 1996) to benzodiazepine tranquillisers (Helman 1981 , Gabe and Lipshitz-Phillips 1982 , 1984 , Gabe and Thorogood 1986 ) and how such meanings were shaped by users' ethnicity and gender (Cooperstock and Lennard 1979 , Gabe and Thorogood 1986 , Ettorre and Riska 1995 .
More recently, with the growing sociological interest in consumption and consumerism (Rief 2008) , attention has increasingly focused on users of pharmaceuticals as knowledgeable and reflexive actors, assessing the risks and benefits and making informed choices in consultation with professionals (Fox 2007 , Fox et al 2005a . Such consumerism in turn is reinforced by UK government policy which constructs patients as experts and exhorts professionals to develop a `partnership' with their patients (Taylor and Bury 2007) . These developments are explored in the paper by to be necessary and at times talked about over-the-counter medicines as a commodity and treated transactions in pharmacies as no different to those in other retail outlets. And pharmacists were aware that they were running a business and that they needed to be sensitive to the danger of losing trade if they resisted selling a product that a customer had requested.
Sociological work on consumerism is not just focused on individual users of health care as knowledgeable and reflexive actors. Attention has also been paid to the way in which users act collectively to represent their interests as members of self help groups, patient advocacy groups and health social movements in the public sphere (Kelleher 2004 . In the case of pharmaceuticals this has involved focusing on how health consumer groups -voluntary sector organisations that represent the interests of patients -engage with the pharmaceutical industry around issues such as the availability of and access to medicines. This provides the focus for the paper by Jones. She explores how health consumer groups in the UK disclose and manage links with pharmaceutical companies in the context of their increasing involvement in the policy process. She focuses on claims that companies engage with groups in order to try and `capture' their policy agenda. Drawing on evidence from group and industry websites and interviews with representative of consumer groups, industry and other health care stake holders she reveals that only around a quarter of groups known to receive financial or in-kind support openly admit to this. Even so Jones rejects the view that this lack of transparency demonstrates that these groups' policy agenda has been `captured'. Rather she points to a coincidence of aims (both sides have an interest in medicines being available), the existence of tacit support for guidelines to manage conflicts and the fact that funding from industry generally represents only a small proportion of these groups' income.
Nonetheless she acknowledges that the lack of transparency as regards disclosing funding strengthens critiques of undue influence and may well reduce policy makers' willingness to treat consumer groups as the legitimate voice of patients in the policy process. Another key area where these issues are very clearly evident is in relation to recent developments in pharmacogenetics and pharmacogenomics (i.e.
the splicing or hybridization of pharmacological and genetic/genomic knowledge in order to predict drug reactions). This is a field of considerable hyperbole and hope regarding a new era of so-called 'personalised', 'bespoke' or 'tailor-made' medicines, construed as the perfect antidote to the 'one-size-fits-all' remedies currently on the market where side-effects or adverse drug reactions (ADRs) are commonplace.
Whilst major pharmaceutical industry interest and investment in this area is relatively recent (little more than 10 years old in fact), pharmacogenetics as a term of reference or organising principle has been around much longer, dating back to the late 1950s. These developments, moreover, generate a number of concerns from a diverse range of constituencies, including potential problems of 'over-segmented' (read 'unprofitable') markets; the proliferation of genetic testing, and; the 'racial politics' of personalised medicine -see Brown and Webster (2004) , and Sneddon (2000) for useful discussions of some of these issues and Hedgecoe (2007) Another key area of hyperbole and hope concerns current research into Mills (1959) , in the Sociological Imagination, classically described as personal troubles and broader public issues of social structure. In potentially holding those in positions of power to account, moreover, and in engaging in informed dialogue and debate with its publics, sociological research on pharmaceuticals admirably demonstrates the continuing importance of the discipline to these developments, discourses and debates. The contributions gathered together in this monograph, we believe, exemplify this promise and potential in an era where the power and force of pharmaceuticals to treat or enhance us, and the interests shaping their development and distribution, manufacture and marketing, look set to grow well into the twenty-first century.
